Understanding EU Annex 1 Expectations
The revised EU GMP Annex 1 (2023) strengthens expectations for sterile manufacturing by promoting a risk-based, science-driven Contamination Control Strategy (CCS) . This summary highlights the core principles and practical steps microbiologists and pharma professionals should focus on to achieve compliance. What is Annex 1? Annex 1 is a part of the EU Good Manufacturing Practice (GMP) guidelines that specifically addresses the manufacture of sterile medicinal products. Its objective is to ensure sterile products are produced and controlled to minimize microbiological, particulate, and pyrogenic contamination. Key Focus Areas in the Revised Annex 1 Below are the primary expectations introduced or emphasised in the 2023 revision: a. Contamination Control Strategy (CCS) A documented, site-wide CCS that identifies contamination risks ...